Herceptin


Also found in: Dictionary, Wikipedia.
Related to Herceptin: HER2

her·cep·tin

(her-sep'tin),
A monoclonal antibody used in treating her 2 neu-positive carcinoma of breast.
Synonym(s): transluzumab

Herceptin

(hər-sĕp′tn)
A trademark for the drug trastuzumab.

Herceptin®

Trastuzumab Molecular oncology A humanized monoclonal antibody to the HER-2 growth factor receptor used to treat metastatic breast CA that overexpresses HER-2. See Breast cancer, Monoclonal antibody.

Herceptin

A brand name for the monoclonal antibody drug TRASTUZUMAB.

Herceptin

A brand name for TRASTUZUMAB.

Patient discussion about Herceptin

Q. Can anyone tell me about herceptin? Can anyone tell me about herceptin? What kind of treatment it is and why it’s popular? Who can be treated? Does it have any side effects?

A. It is a monoclonal antibody. Patients somewhere between 15 – 25 % with breast cancer responded well to this treatment. The patients have in their cancer cells a large amount of a protein called HER2. The treatment for breast cancer patient will depend on the stage of cancer. Side effects of this Herceptin also called trastuzumab are Fatigue, diarrhea, pain, heart problems and reaction to the drug - causing chills, fever and possibly an itchy rash, feeling sick, breathlessness, wheezing, a headache, flushes and faintness. This happens to about half of patients with the first treatment but usually wears off with further treatments.

Q. What side effects are possible with chemotherapy and herceptin? My sister is taking chemotherapy now. Earlier the doctors prescribed herceptin and she had very severe vomiting and anemia. What side effects are possible with chemotherapy and herceptin?

A. The breast cancer treatment mainly focus on the removal of cancer cells and further treatment to prevent its occurance in future. Generally herceptin is the treatment given to destroy cancer cells which have high level of HER2 protein. And chemotherapy is also given to kill cancer cells, which again depends on the type & stage of cancer cells. Herceptin may have the side effects of severe anemia and nausea/ vomiting. Chemotherapy will also have the side effect such as vomiting, hair loss, fatigue, diarrhea, some infections, anemia, swellings, soreness, joint ache. But there is nothing to worry as this is the only treatment available for cancer.

More discussions about Herceptin
References in periodicals archive ?
According to the company, it is potentially the first company to provide patient access to a biosimilar to Herceptin, representing a significant milestone for the overall healthcare system.
In 2006, diagnosed with HER2-positive breast cancer, Walsh was told herceptin might help but was not fully funded in New Zealand.
Genentech requests authorization from the FDA to administer Herceptin as an investigational drug.
Detailed information on Herceptin including product description, safety and efficacy profiles as well as a SWOT analysis.
Adding Perjeta to treatment with Herceptin and chemotherapy resulted in the longest survival observed to date in a clinical study of people with HER2-positive metastatic breast cancer," said Sandra Horning, M.
gt;the new Herceptin Nicola Marshall, of Heaton, Newcastle, was diagnosed with HER2-positive breast cancer more than a year ago and has been part of the region's clinical trial.
An international study found cancer was half as likely to return in women treated with Herceptin.
But the study of Perjeta, which has been approved in the US, found those receiving the treatment were a third less likely to have passed away than those receiving Herceptin and chemotherapy alone.
Doctors are hailing the Herceptin-plus combination, saying it will change treatment in the same way Herceptin did five years ago.
Combining Adriamycin and Herceptin has been shown to cause permanent heart damage.
Herceptin has become something of a watershed drug by signalling both the start of the use of targeted therapies in the fight against cancer and a shift in the way that we consider whether breakthrough new drugs should be available on the NHS.
Based on the Herceptin ToGA phase III study results, presented in May at the American Society for Clinical Oncology Annual Meeting in Orlando, Florida, Genentech may seek regulatory approvals for the use of Herceptin to treat stomach-cancer patients.